YANTAI DONGCHENG BIOCHEMICALS CO., LTD
Stock Code:002675
Development process
YOUR LOCATION:HOME >> ABOUT US

 

YEAR 2017

 

January

The company plans to acquire Nanjing Andi Electronics Zhengye Research and Development Co., Ltd. Through this acquisition, the company will further improve the industrial layout of radionuclides and become a supplier of complete nuclear medicine and nuclear medicine solutions, greatly consolidating the company. Leading position in the field of nuclear medicine

  

 

YEAR 2016

 

August

The company has invested RMB 65 million to control Yitai Pharmaceuticals, and has deployed 188[ReRe] etidronate injection frontier products for nuclear medicine. The company invested RMB 315 million to hold Thailand Zhongtai Bio to achieve low-cost procurement of raw materials and global collaboration

March

The company spent US$70 million to successfully acquire GMS (China), a founding company of domestic diagnostic radiopharmaceutical preparations, and completed the company’s nuclear chemical's entire industrial chain layout from diagnosis to treatment.

  

 

YEAR 2015

 

October

The company invested RMB 750 million to control the domestic No. 1 producer of therapeutic radionuclides, Chengdu Yunke Pharmaceutical, taking a crucial step in the advancement of nuclear medicine.

 

 

YEAR 2014

 

June

The company officially changed its name to “Yantai Dongcheng Pharmaceutical Group Co., Ltd.,” which indicates that the company has basically completed the “change from a single product of raw material medicines to the development of raw material medicines and preparations, focusing on development and group development”.


 

YEAR 2013

 

September

The company invested 85 million yuan in the construction of R&D and quality inspection building, equipped with international high-end scientific research equipment.

May

The company spent RMB 167 million to complete the acquisition of Yantai Ocean Pharmaceuticals

March

The company invested 470 million yuan to raise investment projects "Dongcheng Biopharm Industrial Park" officially started construction

  

 

YEAR 2012

 

May 25

Shenzhen Stock Exchange successfully listed

May 14

Online road show

May

Shenzhen, Shanghai and Beijing Road Show

May 3

Received approval from the Securities Regulatory Commission for approval of Dongcheng IPO

January 6

Dongcheng Pharmaceuticals' listing application is reviewed by the Issuing Committee


 


 

YEAR 2008 — YEAR 2012


Dongcheng Pharmaceutical Listed Preparation Work

January 9

Dongcheng Pharmaceutical Group (Formerly Dongcheng Biochemical) Co., Ltd. Officially Unveiled


 

YEAR 2007

 

December 19

Dongcheng Pharmaceutical Group (Formerly Dongcheng Biochemical) Co., Ltd. was founded and officially launched its listing


 

YEAR 2006

 

Dongyuan Biological Engineering Co., Ltd., a wholly-owned subsidiary, started construction in Funan County, Shandong Province, completing the layout of the upstream of the industrial chain.

 

 

 

YEAR 2002

 

The company merged Yantai North Pharmaceutical Co., Ltd. and the industrial chain extended to the downstream formulation industry.


 

YEAR 2000

 

The company became the first domestic biochemical raw material medicine company to pass the GMP certification of the State Food and Drug Administration


 

YEAR 1999

 

The company was built and the first heparin sodium drug product was put into production


 

YEAR 1998

 

Dongcheng Pharmaceutical Co., Ltd. (formerly Tung Shing Biochemical Co., Ltd.) started construction and kicked off the rapid rise.


 

 

CONTACT US
0535-6391521
Switchboard:86-535-6391521/6391522
Mailbox:zxu@dcb-group.com
Address:No.7 ChangBaiShan Road, Yantai Development Zone, ShanDong, China
COPYRIGHT 2014 YANTAI DONGCHENG BIOCHEMICALS CO., LTD